Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab in locoregionally advanced hypopharyngeal cancer
NCT04539600Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Nov 2020
- Primary completion
- Jul 2022
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in hypopharyngeal squamous cell carcinoma (HSCC), sponsored by Sun Yat-sen University. Primary endpoint: Progression-free Survival at 1 year. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
hypopharyngeal squamous cell carcinoma (HSCC)
Beyond the preview
Go deeper on NCT04539600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04539600.